QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NASDAQ:BCAB

BioAtla (BCAB) Competitors

$1.51
-0.12 (-7.36%)
(As of 10/3/2023 ET)
Compare
Today's Range
$1.50
$1.66
50-Day Range
$1.51
$3.00
52-Week Range
$1.50
$11.73
Volume
246,059 shs
Average Volume
512,721 shs
Market Capitalization
$72.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.83

BCAB vs. CGEN, TSBX, CDTX, CLLS, LIFE, NSTG, JSPR, CCCC, ATHA, and CRDF

Should you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Compugen (CGEN), Turnstone Biologics (TSBX), Cidara Therapeutics (CDTX), Cellectis (CLLS), aTyr Pharma (LIFE), NanoString Technologies (NSTG), Jasper Therapeutics (JSPR), C4 Therapeutics (CCCC), Athira Pharma (ATHA), and Cardiff Oncology (CRDF). These companies are all part of the "biological products, except diagnostic" industry.

BioAtla vs.

Compugen (NASDAQ:CGEN) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.

Compugen currently has a consensus target price of $8.33, indicating a potential upside of 805.90%. BioAtla has a consensus target price of $14.83, indicating a potential upside of 882.34%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Compugen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compugen
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
BioAtla
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

13.3% of Compugen shares are owned by institutional investors. Comparatively, 71.7% of BioAtla shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 8.4% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioAtla's return on equity of -46.35% beat Compugen's return on equity.

Company Net Margins Return on Equity Return on Assets
CompugenN/A -46.35% -37.71%
BioAtla N/A -77.19%-58.34%

Compugen received 283 more outperform votes than BioAtla when rated by MarketBeat users. Likewise, 65.15% of users gave Compugen an outperform vote while only 62.07% of users gave BioAtla an outperform vote.

CompanyUnderperformOutperform
CompugenOutperform Votes
301
65.15%
Underperform Votes
161
34.85%
BioAtlaOutperform Votes
18
62.07%
Underperform Votes
11
37.93%

Compugen has a beta of 2.66, suggesting that its share price is 166% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Compugen has higher revenue and earnings than BioAtla. Compugen is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$7.50M10.63-$33.69M-$0.40-2.30
BioAtla$250K288.71-$106.48M-$2.65-0.57

In the previous week, Compugen had 13 more articles in the media than BioAtla. MarketBeat recorded 13 mentions for Compugen and 0 mentions for BioAtla. Compugen's average media sentiment score of 0.94 beat BioAtla's score of 0.35 indicating that BioAtla is being referred to more favorably in the news media.

Company Overall Sentiment
Compugen Neutral
BioAtla Positive

Summary

Compugen beats BioAtla on 10 of the 17 factors compared between the two stocks.


Get BioAtla News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCAB vs. The Competition

MetricBioAtlaBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$72.18M$2.66B$4.44B$6.22B
Dividend YieldN/A2.27%5.94%7.83%
P/E Ratio-0.577.41126.5413.27
Price / Sales288.71158.532,896.2068.08
Price / CashN/A25.9721.4722.77
Price / Book0.403.343.814.57
Net Income-$106.48M$63.74M$121.45M$181.79M
7 Day Performance-13.71%-4.87%-2.26%-2.07%
1 Month Performance-42.37%-12.38%-8.21%-9.25%
1 Year Performance-81.31%12.45%6.56%1.74%

BioAtla Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGEN
Compugen
1.7515 of 5 stars
$0.96
-4.0%
$8.33
+765.1%
+46.1%$83.45M$7.50M-2.4169Short Interest ↓
Analyst Revision
News Coverage
Gap Down
TSBX
Turnstone Biologics
1.8701 of 5 stars
$3.56
+0.8%
$19.00
+433.7%
N/A$81.32M$39.97M0.00108News Coverage
CDTX
Cidara Therapeutics
2.2384 of 5 stars
$0.98
+1.0%
$4.67
+376.2%
+46.5%$88.45M$64.29M-7.5473
CLLS
Cellectis
2.1138 of 5 stars
$1.62
+1.3%
$9.75
+501.9%
-34.5%$90.04M$25.73M-0.81231News Coverage
LIFE
aTyr Pharma
2.386 of 5 stars
$1.59
+2.6%
$20.75
+1,205.0%
-49.7%$90.71M$10.39M-1.2965Short Interest ↓
NSTG
NanoString Technologies
1.9654 of 5 stars
$1.61
-2.4%
$16.17
+904.1%
-88.0%$76.56M$127.26M-0.45703Gap Up
JSPR
Jasper Therapeutics
2.2214 of 5 stars
$0.68
-4.2%
$6.37
+840.9%
-7.9%$75.01MN/A-0.6835Short Interest ↑
CCCC
C4 Therapeutics
1.8111 of 5 stars
$1.88
-1.6%
$10.13
+438.6%
-80.6%$92.48M$31.10M-0.66146Short Interest ↑
ATHA
Athira Pharma
2.3978 of 5 stars
$1.96
-1.0%
$11.33
+478.2%
-36.4%$74.60MN/A-0.6963Positive News
CRDF
Cardiff Oncology
1.8272 of 5 stars
$1.62
+0.6%
$9.00
+455.6%
-15.6%$72.38M$390,000.00-1.8025Short Interest ↑
Gap Down
High Trading Volume

Related Companies and Tools

This page (NASDAQ:BCAB) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -